A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Despite significant medical advances, infective endocarditis (IE) remains an infection associated with high morbidity and mortality. The objective was to assess the safety and efficacy of high-dose daptomycin, defined as ≥ 8 mg/kg/day, in patients with confirmed or suspected staphylococcal and/or enterococcal IE. METHODS: This was a multicentre, retrospective observational study (2005-11). Adult patients, not undergoing haemodialysis, with blood cultures positive for staphylococci or enterococci and a definitive or possible diagnosis of IE, who received daptomycin ≥ 8 mg/kg/day (based on total body weight) for ≥ 72 h were included. RESULTS: Seventy patients met the inclusion criteria and comprised 33 (47.1%) with right-sided IE (RIE), 35 (50%) with left-sided IE (LIE) and 2 with both RIE and LIE. Several patients had concomitant sites of infection, with bone/joint infection being most prevalent (12.9%). Sixty-five patients received daptomycin as salvage therapy. Pathogens were isolated from 64 patients, with methicillin-resistant Staphylococcus aureus as the most common organism (84.4%), followed by vancomycin-resistant Enterococcus faecium (7.8%). The median (IQR) daptomycin dose was 9.8 mg/kg/day (8.2-10.0 mg/kg/day), and was similar in RIE and LIE patients (9.8 and 9.3 mg/kg/day, respectively). A total of 24 (34.3%) received combination therapy. For those patients with pathogens isolated (n = 64), the organism was eradicated in 57 (89.1%) patients. Among 64 clinically evaluable patients, 55 (85.9%) achieved clinical success. No patients required discontinuation of high-dose daptomycin due to creatine phosphokinase elevations. CONCLUSIONS: Patients with both RIE and LIE had successful outcomes with high-dose daptomycin therapy. Additional clinical trials evaluating high daptomycin dosages in patients with IE are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Self-citationProposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis
Li, J. S., Sexton, D. J., Mick, N., Nettles, R., Fowler, V. G., Ryan, T., Bashore, T., & Corey, G. R. (2000) · Clinical Infectious Diseases · doi:10.1086/313753 · Cited by 4,027
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir034 · Cited by 1,599
Self-citationDaptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Self-citationStaphylococcus aureus Endocarditis: A Consequence of Medical Progress
Fowler, V. G., Miro, J. M., Hoen, B., Cabell, C. H., Abrutyn, E., Rubinstein, E., Corey, G. R., Spelman, D., Bradley, S. F., Barsic, B., et al. (2005) · JAMA · doi:10.1001/jama.293.24.3012 · Cited by 1,174
Self-citationEmergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat
Grundmann, H., Aires-de-Sousa, M., Boyce, J., & Tiemersma, E. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68853-3 · Cited by 1,101
Arbeit, R. D., Maki, D., Tally, F. P., Campanaro, E., Eisenstein, B. I., & Daptomycin 98-01 and 99-01 Investigators (2004) · Clinical Infectious Diseases · doi:10.1086/420818 · Cited by 689
Lodise, T. P., Graves, J., Evans, A., Graffunder, E., Helmecke, M., Lomaestro, B. M., & Stellrecht, K. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00113-08 · Cited by 553
Kullar, R., Davis, S. L., Levine, D. P., & Rybak, M. J. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir124 · Cited by 463
Self-citationHealth Care–Associated Native Valve Endocarditis: Importance of Non-nosocomial Acquisition
Benito, N., Miró, J. M., de Lazzari, E., Cabell, C. H., del Río, A., Altclas, J., Commerford, P., Delahaye, F., Dragulescu, S., Giamarellou, H., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00004 · Cited by 277
Sakoulas, G., Alder, J., Thauvin-Eliopoulos, C., Moellering, R. C., & Eliopoulos, G. M. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1581-1585.2006 · Cited by 262
Self-citationContemporary Epidemiology and Prognosis of Health Care–Associated Infective Endocarditis
Fernández‐Hidalgo, N., Almirante, B., Tornos, P., Pigrau, C., Sambola, A., Igual, A., & Pahissa, A. (2008) · Clinical Infectious Diseases · doi:10.1086/592576 · Cited by 217
Akins, R. L., & Rybak, M. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.2.454-459.2001 · Cited by 179
Self-citation(2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir353 · Cited by 172
Persistence in Staphylococcus aureus bacteremia: Incidence, characteristics of patients and outcome
Khatib, R., Johnson, L. B., Fakih, M. G., Riederer, K., Khosrovaneh, A., Shamse Tabriz, M., Sharma, M., & Saeed, S. (2006) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540500372846 · Cited by 168
Figueroa, D. A., Mangini, E., Amodio‐Groton, M., Vardianos, B., Melchert, A., Fana, C., Wehbeh, W., Urban, C. M., & Segal‐Maurer, S. (2009) · Clinical Infectious Diseases · doi:10.1086/600039 · Cited by 153
Kullar, R., Davis, S. L., Levine, D. P., Zhao, J. J., Crank, C. W., Segreti, J., Sakoulas, G., Cosgrove, S. E., & Rybak, M. J. (2011) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.6.527 · Cited by 136
Self-citationSafety and Clinical Outcomes when Utilizing High-Dose (≥8 mg/kg) Daptomycin Therapy
Moise, P. A., Hershberger, E., Amodio-Groton, M. I., & Lamp, K. C. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m085 · Cited by 136
Tsuji, B. T., & Rybak, M. J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.7.2735-2745.2005 · Cited by 113
Self-citationTedesco, K. L., & Rybak, M. J. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.1.41.34802 · Cited by 110
Self-citationDaptomycin in the Treatment of Patients with Infective Endocarditis: Experience from a Registry
Levine, D. P., & Lamp, K. C. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.07.011 · Cited by 105
Self-citationHall, A. D., Steed, M. E., Arias, C. A., Murray, B. E., & Rybak, M. J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06439-11 · Cited by 101
Self-citationFridkin, S. K., Lawton, R. M., Edwards, J. R., Tenover, F. C., McGowan, J. E., & Gaynes, R. P. (2002) · Emerging infectious diseases · doi:10.3201/eid0807.010465 · Cited by 95
Daptomycin Dose-Effect Relationship against Resistant Gram-Positive Organisms
Cha, R., Grucz, R. G., & Rybak, M. J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1598-1603.2003 · Cited by 95
Self-citationKatz, D. E., Lindfield, K. C., Steenbergen, J. N., Benziger, D. P., Blackerby, K. J., Knapp, A. G., & Martone, W. J. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01854.x · Cited by 93
Rose, W. E., Leonard, S. N., & Rybak, M. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00102-08 · Cited by 90
Self-citationRose, W. E., Leonard, S. N., Sakoulas, G., Kaatz, G. W., Zervos, M. J., Sheth, A., Carpenter, C. F., & Rybak, M. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00869-07 · Cited by 81
Self-citationMortin, L. I., Li, T., Van Praagh, A. D. G., Zhang, S., Zhang, X.-X., & Alder, J. D. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00738-06 · Cited by 80
Rose, W. E., Rybak, M. J., & Kaatz, G. W. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm170 · Cited by 78
Self-citationHigh-Dose Daptomycin for Cardiac Implantable Electronic Device-Related Infective Endocarditis
Durante‐Mangoni, E., Casillo, R., Bernardo, M., Caianiello, C., Mattucci, I., Pinto, D., Agrusta, F., Caprioli, R., Albisinni, R., Ragone, E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir805 · Cited by 67
Mohr, J., Friedrich, L. V., Yankelev, S., & Lamp, K. C. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.12.007 · Cited by 65
Chambers, H. F., Basuino, L., Diep, B. A., Steenbergen, J., Zhang, S., Tattevin, P., & Alder, J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01307-08 · Cited by 42
Cunha, B. A., Mickail, N., & Eisenstein, L. E. (2007) · Heart & Lung · doi:10.1016/j.hrtlng.2007.02.012 · Cited by 38
Kennedy, S., & Chambers, H. F. “. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.9.1522 · Cited by 37
Cunha, B. A., Krol, V., & Kodali, V. (2008) · Heart & Lung · doi:10.1016/j.hrtlng.2007.04.003 · Cited by 33
A Better Future for Patients with Restless Legs Syndrome
Winkelman, J. W. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.11.005 · Cited by 12
Cited by
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Habib, G., Lancellotti, P., Antunes, M. J., Bongiorni, M. G., Casalta, J.-P., Del Zotti, F., Dulgheru, R., El Khoury, G., Erba, P. A., Iung, B., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv319 · Cited by 4,997
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Self-citation2023 ESC Guidelines for the management of endocarditis
Delgado, V., Ajmone Marsan, N., de Waha, S., Bonaros, N., Brida, M., Burri, H., Caselli, S., Doenst, T., Ederhy, S., Erba, P. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad193 · Cited by 1,754
Hassoun, A., Linden, P. K., & Friedman, B. (2017) · Critical Care · doi:10.1186/s13054-017-1801-3 · Cited by 604
“Furthermore, some studies suggest prior vancomycin failure is correlated with the acquisition of heteroresistance and reduced success of daptomycin therapy [12, 15, 16].”
Background
Metadata
- Authors
- Kullar, R., Casapao, A. M., Davis, S. L., Levine, D. P., Zhao, J. J., Crank, C. W., Segreti, J., Sakoulas, G., Cosgrove, S. E., & Rybak, M. J.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- Detroit Medical Center (US)
- Rush University Medical Center (US)
- Sharp Memorial Hospital (US)
- Johns Hopkins University (US)
- Corresponding author
- Rybak, M. J.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-08-08
- Volume
- 68
- Issue
- 12
- Pages
- 2921-2926
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- PMC
- PMC3820108
- OpenAlex
- W2096479937
- Cited by
- 99
- References
- 36
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 2 · 2023: 4 · 2022: 5 · 2021: 4 · 2020: 8 · 2019: 7 · 2018: 5 · 2017: 8 · 2016: 17 · 2015: 22 · 2014: 8
- FWCI
- 11.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Antimicrobial Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- U.S. Public Health Service (R21A1092055-01)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Keywords
- daptomycin, high-dose daptomycin, infective endocarditis, staphylococcal endocarditis, enterococcal endocarditis, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, right-sided endocarditis, left-sided endocarditis, salvage therapy, combination therapy, treatment efficacy, drug safety, creatine kinase elevation
- MeSH terms
- Adult, Anti-Bacterial Agents, Blood, Endocarditis, Female, Humans, Male, Middle Aged, Retrospective Studies, Staphylococcus aureus, Treatment Outcome, Gram-Positive Bacterial Infections, Enterococcus, Daptomycin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.